[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-438339-105":59,"doc-detail-438339-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cellular-immunotherapy-for-prostate-cancer-lessons-learned-from-15-years-of-sipuleucel-t","Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T","","Cellular Immunotherapy for Prostate Cancer reviews the clinical and real-world evidence accumulated over 15 years for sipuleucel-T in metastatic castration-resistant prostate cancer. The review summarizes its personalized, autologous mechanism that activates immune cells to recognize prostatic acid phosphatase and demonstrates survival benefit supported by trials and subsequent data. It highlights immune and biologic responses, patient-specific factors linked to longer survival, and the need to optimize appropriate utilization within current advanced prostate cancer treatment paradigms.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cellular-immunotherapy-for-prostate-cancer-lessons-learned-from-15-years-of-sipuleucel-t/438339/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cellular-immunotherapy-for-prostate-cancer-lessons-learned-from-15-years-of-sipuleucel-t/438339.png","ImageObject",300,407,{"name":92,"@type":93},"ahduag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is sipuleucel-T and how does it work in metastatic castration-resistant prostate cancer?","Question",{"text":112,"@type":113},"Sipuleucel-T is a personalized, autologous immunotherapy designed to activate a patient’s immune system using ex vivo exposure to prostatic acid phosphatase, enabling immune cells to recognize and target prostate cancer cells expressing PAP.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence supports sipuleucel-T’s survival benefit?",{"text":117,"@type":113},"In the IMPACT Phase III trial, sipuleucel-T showed a statistically significant improvement in median overall survival versus placebo, and later clinical trials and real-world data further supported clinical benefit and described immune and biologic responses.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is maximizing appropriate clinical utilization of sipuleucel-T important?",{"text":121,"@type":113},"Although multiple life-prolonging modalities are available for mCRPC, sipuleucel-T has a unique mechanism and remains an important option; estimates suggest only about 10% of eligible patients receive it, indicating underutilization in current practice.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},438339,1790877673,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},3985747870414,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Wiley  \nProstate Cancer  \nVolume 2025, Article ID 9766669, 15 pages [https://doi.org/10.1155/proc/9766669](https://doi.org/10.1155/proc/9766669)  \nReview Article  \nCellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T  \nNeal D. Shore , 1 Emmanuel S. Antonarakis,2 Jason Hafron,3 Kelvin A. Moses,4 Christopher Pieczonka,5 Benjamin Lowentritt,6 Nadeem Sheikh,7 Daniel J. George,8 and Tanya Barauskas Dorf9  \n1 Genitourinary Oncology Center of Excellence, START Carolinas/Carolina Urologic Research Center, Myrtle Beach,  \nSouth Carolina, USA  \n2 University of Minnesota Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA  \n3 Clinical Research, Michigan Institute of Urology, West Bloomfeld, Michigan, USA  \n4 Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee, USA  \n5 Clinical Research, Associated Medical Professionals of NY, Syracuse, New York, USA  \n6 Minimally Invasive Surgery and Robotics, Chesapeake Urology, Towson, Maryland, USA  \n7 Research and Manufacturing Science, Dendreon Pharmaceuticals, Seattle, Washington, USA  \n8 Medical Oncology, Duke University Cancer Center, Durham, North Carolina, USA  \n9 Department of Medical Oncology and Terapeutics Research, City of Hope National Cancer Center, Duarte, California, USA Correspondence should be addressed to Neal D. Shore; [nshore@auclinics.com](nshore@auclinics.com)  \nReceived 27 May 2025; Revised 2 October 2025; Accepted 3 December 2025  \nAcademic Editor: Subrata Bhattacharjee  \nCopyright © 2025 Neal D. Shore et al. Prostate Cancer published by John Wiley & Sons Ltd. Tis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \nTe frst cellular cancer immunotherapy, sipuleucel-T, was approved for metastatic castration-resistant prostate cancer (mCRPC) patients 15 years ago. Since then, the therapeutic landscape of advanced prostate cancer has signifcantly evolved. Sipuleucel-T is a personalized, autologous immunotherapy that activates the patient’s immune system to target prostatic acid phosphatase (PAP)–expressing tumor cells and has demonstrated survival beneft in patients with nonopioid requiring mCRPC. Subsequent clinical trials and abundant real-world data have provided further evidence of this novel immunotherapy’s clinical beneft for patients with mCRPC, as well as demonstrating the numerous immune and biologic responses that sipuleucel-T induces. Tese data have also identifed patient-specifc factors associated with longer survival, including race, baseline disease burden, and treatment-induced immune responses. Despite the addition of multiple life-prolonging therapeutic modalities now available to treat patients with mCRPC, the mechanism of action of sipuleucel-T remains unique for patients with advanced prostate cancer. Terefore, maximizing the appropriate clinical utilization of sipuleucel-T in patients with mCRPC within current treatment paradigms is essential.  \nKeywords: immunotherapy; prostate cancer; sipuleucel-T  \n1. Introduction  \nBefore 2010, advanced prostate cancer management typically involved chronic androgen deprivation therapy followed by treatment with agents such as mitoxantrone or docetaxel chemotherapy in a subset of patients with symptomatic  \nmetastatic castration-resistant prostate cancer (mCRPC) [1] . Tanks to intensifed clinical research and investment, patient care for advanced prostate cancer has evolved significantly based on a greater understanding of cancer biology and novel tumor profling [1, 2] . Multiple new agents targeting prostate cancer through diferent mechanisms of  \n2 Prostate Cancer  \naction have been approved, extending overall survival (OS) rather than merely delaying disease progression [1, 2] . A pivotal moment for this shift was the 2010 approval of sipuleucel-T for patients with asymptomatic or minima","cbCaibyKCVCo8MzV","https://ap.wps.com/l/cbCaibyKCVCo8MzV","pdf",1339234,15,"English","# Introduction\n# Immunotherapy to Treat Prostate Cancer","[{\"question\":\"What is sipuleucel-T and how does it work in metastatic castration-resistant prostate cancer?\",\"answer\":\"Sipuleucel-T is a personalized, autologous immunotherapy designed to activate a patient’s immune system using ex vivo exposure to prostatic acid phosphatase, enabling immune cells to recognize and target prostate cancer cells expressing PAP.\"},{\"question\":\"What evidence supports sipuleucel-T’s survival benefit?\",\"answer\":\"In the IMPACT Phase III trial, sipuleucel-T showed a statistically significant improvement in median overall survival versus placebo, and later clinical trials and real-world data further supported clinical benefit and described immune and biologic responses.\"},{\"question\":\"Why is maximizing appropriate clinical utilization of sipuleucel-T important?\",\"answer\":\"Although multiple life-prolonging modalities are available for mCRPC, sipuleucel-T has a unique mechanism and remains an important option; estimates suggest only about 10% of eligible patients receive it, indicating underutilization in current practice.\"}]","Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T | PDF",1790685050,38]